- Next Science Limited is an emerging medical technology company, established in 2012, headquartered in Australia.
- Next Science is commercialising its unique XbioTM technology platform through products that provide a non-toxictreatment for biofilm based infections.
- Biofilms pose a far-reaching threat to humans, animals and the environment, representing 90% of all bacteria.
- Bacteria protected by a biofilm can be 1,000x more resistant to antibiotics than free floating bacteria.
- Over 70,000 patients have been treated with Xbio technology in the US market to date.
- Next Science has 4 FDA cleared products currently in the US market to treat and manage surgical site infectionsand chronic wounds, and expects to have 8 products in market by the end of 2019 .
- Distribution agreements with major multinationals validate the Company’s Xbio technology .
- Next Science has a rapid growth trajectory with an extensive pipeline of products in both medical devices, OTCproducts and pharmaceutical applications
- Unique, non-toxic platform technology with proven efficacy in eradicating biofilm andbacteria.
- Addresses a clear unmet medical need and avoids creating antibacterial resistance
- Commercial demand proven by early sales agreements with global industry leaders . Zimmer Biomet (global leader in joint replacements) for Bactisure surgical lavage (wash) 3M (a global leader in wound care) for BlastX wound gel
- Multiple products targeting high value market segments with unmet needs
- 8 products expected to be in market by end 2019
- Extensive product pipeline across medical devices, OTC drugs and prescriptionpharmaceuticals
- High margin and highly scalable production, with contract manufacturing in 4 countries
- Broad international IP protection with 15 granted patents and 47 applications pending
- Rapid sales growth through leveraging global distribution partners, launching new productsinto new markets, and via geographic expansion, with 8 products in market by end 2019
- Next Science expects to benefit from multiple compounding growth drivers in 2019 and beyond:
- Increased market penetration of existing products in the US market
- Geographic expansion of sales outside the US- with entry to Australia and Europe expected in 2019
- Development and commercialisation of new products and applications in human health
- Next Science expects to have 8 products in market by end 2019, up from 2 in early 2018
- Extension of Xbio technology into applications outside human health .
- Manufacturing and production is highly scalable, using FDA or CE Mark audited contract manufacturers in theUSA, Europe, Australia and Mexico
- Circa 500% revenue growth to A$20m in 2019 implied in management performance hurdles under the LTI plan
It should do extremely well in short and medium term IMO and a potential multibagger for long term.
It was very hard to get any stock in the IPO . Managed to get a tiny allocation in IPO .
DYOR
ALL IMO
GLTAH
- Forums
- ASX - By Stock
- NXS
- IPO - Next Science Limited
IPO - Next Science Limited, page-9
-
-
- There are more pages in this discussion • 208 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add NXS (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $58.43M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 19.0¢ | $21.32K | 107.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12957 | 0.190 |
5 | 76783 | 0.185 |
6 | 118894 | 0.180 |
2 | 23800 | 0.175 |
1 | 17500 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 5000 | 1 |
0.230 | 1298 | 1 |
0.245 | 400 | 1 |
0.250 | 28990 | 2 |
0.265 | 20000 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NXS (ASX) Chart |